Hikma PharmaceuticalsHKMPY 87 Market Cap is $4,279 Mil as of Jun. 30, 2026. GuruFocus rates HKMPY with a GF Score™ of 87/100 and a GF Value™ of $56.71 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,020 Drug Manufacturers companies, Hikma Pharmaceuticals ranks better than 92.16% on this metric.
Hikma Pharmaceuticals's quarterly market cap
increased
from Dec. 2024 ($5,512 Mil) to Jun. 2025 ($6,149 Mil) but then
declined
from Jun. 2025 ($6,149 Mil) to Dec. 2025 ($4,614 Mil).
Hikma Pharmaceuticals's annual market cap
increased
from Dec. 2023 ($5,020 Mil) to Dec. 2024 ($5,512 Mil) but then
declined
from Dec. 2024 ($5,512 Mil) to Dec. 2025 ($4,614 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Hikma Pharmaceuticals's Enterprise Value for Today is $5,623 Mil.
Hikma Pharmaceuticals (OTCPK:HKMPY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hikma Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hikma Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hikma Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Hikma Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Hikma Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hikma Pharmaceuticals (HKMPY) has a Market Cap of $4,279 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hikma Pharmaceuticals and its competitors. According to the industry distribution chart, Hikma Pharmaceuticals ranks #80 out of 1020 companies in the Drug Manufacturers industry, placing it in the top 7.8%.
Is Hikma Pharmaceuticals' Market Cap too high?
Hikma Pharmaceuticals' current Market Cap is $4,279 Mil. The Drug Manufacturers industry median Market Cap is 206.61. Hikma Pharmaceuticals' value of $4,279 Mil is 1971.1% above this industry median. Based on the distribution chart, Hikma Pharmaceuticals ranks #80 out of 1020 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hikma Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hikma Pharmaceuticals' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Hikma Pharmaceuticals ranks #80 out of 1020 companies for Market Cap. This places Hikma Pharmaceuticals in the top 8% of its industry — outperforming the majority of peers. The industry median Market Cap is 206.61. Hikma Pharmaceuticals' value of $4,279 Mil is 1971.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 206.61, based on 1,020 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hikma Pharmaceuticals's current Market Cap of $4,279 Mil is 1971.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Hikma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 206.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hikma Pharmaceuticals's current Market Cap is $4,279 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hikma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hikma Pharmaceuticals (HKMPY) is currently considered Modestly Undervalued. The stock's GF Value™ is $56.71, compared to a current price of $41.23 — trading 27.3% below its estimated fair value. The current Market Cap is $4,279 Mil and 1971.1% above the Drug Manufacturers industry median of 206.61. Hikma Pharmaceuticals' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Hikma Pharmaceuticals (HKMPY), the current Market Cap is $4,279 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hikma Pharmaceuticals (HKMPY) Overvalued in 2026?
Based on GuruFocus' analysis, Hikma Pharmaceuticals stock appears to be undervalued.
The current stock price of $41.23 is trading 27.3% below its estimated GF Value™ of $56.71.
GuruFocus considers Hikma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKMPY:
Market Cap: $4,279 Mil
GF Value™: $56.71 vs. price of $41.23 (27.3% below fair value)
Industry Position: 1971.1% above the Drug Manufacturers median (#80 of 1020)
No single metric tells the full story. See the HKMPY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, Rx, and branded. The majority of the company's revenue is generated from its injectables segment, which supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue-generating market, followed by the Middle East and North Africa, the United Kingdom, Europe, and the rest of the world.
87GF Score
Get the complete analysis for HKMPY
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKMPY has been successfully added to your 
